AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00683865
Drug: Avelox (Moxifloxacin, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg po od for 14 days
Trial: NCT03919656
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
Trial: NCT03992365
Drug: Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.
Trial: NCT00399126
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine oral dose
Trial: NCT00399126
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel IV
Trial: NCT01191034
Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod.
Trial: NCT02677350
Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-fistula injections
Trial: NCT04500717
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT04500717
Drug: Almonertinib plus carboplatin and pemetrexed
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Trial: NCT01841593
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isentress 400mg tablet taken twice daily
Trial: NCT01841593
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
Trial: NCT02740192
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine was used for the periarticular injection
Trial: NCT02740192
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine was used for the periarticular injection
Trial: NCT00356226
Drug: clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199017
Drug: Asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00199017
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199017
Drug: Vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199017
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01172041
Drug: 18-FDG
RxNorm normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mCi
Trial: NCT01223378
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.005% ophthalmic solution, QD 28 days
Trial: NCT00423878
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
Trial: NCT00423878
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
Trial: NCT00423878
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
Trial: NCT00423878
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switching medication to aripiprazole for schizophrenia for up to 6 months in study
Trial: NCT00850811
Drug: PEP005 (ingenol mebutate) Gel
RxNorm normalized name: Ingenol Mebutate Topical Gel
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEP005 (ingenol mebutate) Gel, 0.01%
Trial: NCT00492505
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00492505
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00492505
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05681598
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
Trial: NCT00065156
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
Trial: NCT05716126
Drug: [14C]Iruplinalkib (WX-0593)
DrugBank: Iruplinalkib (DB17494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
Trial: NCT00862043
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg t.i.d.
Trial: NCT03614663
Drug: ZYN002 - Cannabidiol Transdermal Gel
RxNorm normalized name: (-)-trans-cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
Trial: NCT00372775
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
Trial: NCT01970410
Drug: teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 mg oral teriflunomide daily
Trial: NCT04257487
Drug: Sulodexide
RxNorm normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 soft capsules of Vessel® 250 LSU BID for 12 months
Trial: NCT04257487
Drug: Sulodexide and placebo
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
Trial: NCT02691169
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
Trial: NCT02299349
Drug: bupivacaine liposome suspension
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine liposome suspension periarticular injection
Trial: NCT00352131
Drug: HuC242-DM4
RxNorm normalized name: huMy9-6-DM4
DrugBank: AVE9633 (DB06318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
Trial: NCT01223924
Drug: M2ES
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: M2ES IV 7.5mg-90mg
Trial: NCT06188221
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
Trial: NCT04046159
Drug: Low-dose tamoxifen
RxNorm normalized name: ethinyl estradiol
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
Trial: NCT04169256
Drug: HYR-PB21
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
Trial: NCT04169256
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
Trial: NCT03709706
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered to eligible participants.
Trial: NCT00649272
Drug: Oxybutynin Chloride Extended-Release Tablets, 15 mg
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg, single dose fasting
Trial: NCT01356524
Drug: Additional vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The progesterone dose will be raised from 200 mg daily to 300 mg daily
Trial: NCT01099566
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
Trial: NCT03107169
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
Trial: NCT00449774
Drug: Lamotrigine IR tablets
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine IR tablets will be available in dose strength of 200 mg.
Trial: NCT00449774
Drug: Lamotrigine ODT tablets
RxNorm normalized name: Lamotrigine Orally Disintegrating Tablets
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine ODT tablets will be available in dose strength of 200 mg.
Trial: NCT02803749
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02282709
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 mg once daily
Trial: NCT02282709
Drug: asunaprevir
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 100 mg BID
Trial: NCT00001752
Drug: L-arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001752
Drug: Estrogen
RxNorm normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01100151
Drug: RDC-1036 (ALKS 37)
RxNorm normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT00389194
Drug: continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
RxNorm normalized name: zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01558960
Drug: IVit Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVit injections of Melphalan
Trial: NCT00278928
Drug: Liposyn III 20% (lipid infusion)
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00278928
Drug: Intralipid 20% (lipid infusion)
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03878979
Drug: Nivolumab 480mg and surgical resection
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One dose of Nivolumab 480mg given four weeks prior to surgical resection.
Trial: NCT04241640
Drug: Nefopam 20 MG/ML
RxNorm normalized name: nefopam 20 MG/ML
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
Trial: NCT00362960
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00362960
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00074646
Drug: CC-8490
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00111241
Drug: aromatase inhibitors (letrozole, anastrozole)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
Trial: NCT00137176
Drug: Rebif
RxNorm normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rebif 44mcg TIW
Trial: NCT00794768
Drug: desloratadine 5 mg
RxNorm normalized name: desloratadine 5 MG
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarinex 5 mg daily x 7 days
Trial: NCT00794768
Drug: fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allegra 180 mg daily x 7 days
Trial: NCT02419534
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative to treat constipation
Trial: NCT02419534
Drug: Polyethylene glycol with Diltiazem
RxNorm normalized name: Polyethylene Glycol
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laxative and topical calcium channel blocker
Trial: NCT00578201
Drug: radiochemotherapy,combination Cetuximab-FOLFOX
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
Trial: NCT02502032
Drug: Cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different groups received different pretreatments of cisatracurium.
Trial: NCT01506388
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 50 Ug , vaginally every 4-6 hours
Trial: NCT02961998
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each group will receive sorafenib as basic treatment.
Trial: NCT03035188
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
Trial: NCT02577991
Drug: Decadron
RxNorm normalized name: Decadron
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
Trial: NCT02577991
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
Trial: NCT00790413
Drug: iodine I 131 metaiodobenzylguanidine
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00790413
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790413
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00790413
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04248998
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg twice a day
Trial: NCT04248998
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq
Trial: NCT04174339
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
Trial: NCT04174339
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
Trial: NCT01042093
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 5mg/ml (49.25 ml)
Trial: NCT01042093
Drug: Toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toradol 30mg/ml (1 ml)
Trial: NCT01042093
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
Trial: NCT00295425
Drug: Cyclosporine A versus mycophenolate mofetil for psoriasis
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02841982
Drug: single dose ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified.
Trial: NCT02841982
Drug: Morphine given as IPCA(intravenous patient controlled analgesia)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
Trial: NCT03482973
Drug: Bupivacaine Group
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
Trial: NCT00946920
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).